These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 19158197)
1. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome. de Lind van Wijngaarden RF; de Klerk LW; Festen DA; Duivenvoorden HJ; Otten BJ; Hokken-Koelega AC J Clin Endocrinol Metab; 2009 Apr; 94(4):1274-80. PubMed ID: 19158197 [TBL] [Abstract][Full Text] [Related]
2. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome. Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome. de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938 [TBL] [Abstract][Full Text] [Related]
4. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial. de Lind van Wijngaarden RF; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; van Leeuwen M; Haring DA; Bocca G; Mieke Houdijk EC; Hokken-Koelega AC J Clin Endocrinol Metab; 2009 Oct; 94(10):3763-71. PubMed ID: 19622627 [TBL] [Abstract][Full Text] [Related]
5. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment. Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment. de Lind van Wijngaarden RF; Cianflone K; Gao Y; Leunissen RW; Hokken-Koelega AC J Clin Endocrinol Metab; 2010 Apr; 95(4):1758-66. PubMed ID: 20173020 [TBL] [Abstract][Full Text] [Related]
7. Effects of 8 years of growth hormone treatment on scoliosis in children with Prader-Willi syndrome. Grootjen LN; Rutges JPHJ; Damen L; Donze SH; Juriaans AF; Kerkhof GF; Hokken-Koelega ACS Eur J Endocrinol; 2021 May; 185(1):47-55. PubMed ID: 33886496 [TBL] [Abstract][Full Text] [Related]
8. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment. Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Van Alfen AA; Van Leeuwen M; Van Wieringen H; Wegdam-den Boer ME; Zwaveling-Soonawala N; Hokken-Koelega AC J Clin Endocrinol Metab; 2015 Apr; 100(4):1609-18. PubMed ID: 25668198 [TBL] [Abstract][Full Text] [Related]
9. IGF-1 Levels, Complex Formation, and IGF Bioactivity in Growth Hormone-Treated Children With Prader-Willi Syndrome. Bakker NE; van Doorn J; Renes JS; Donker GH; Hokken-Koelega AC J Clin Endocrinol Metab; 2015 Aug; 100(8):3041-9. PubMed ID: 26050733 [TBL] [Abstract][Full Text] [Related]
10. Adiponectin levels in prepubertal children with Prader-Willi syndrome before and during growth hormone therapy. Festen DA; van Toorenenbergen A; Duivenvoorden HJ; Hokken-Koelega AC J Clin Endocrinol Metab; 2007 Apr; 92(4):1549-54. PubMed ID: 17264186 [TBL] [Abstract][Full Text] [Related]
11. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database. Bakker NE; Lindberg A; Heissler J; Wollmann HA; Camacho-Hübner C; Hokken-Koelega AC; J Clin Endocrinol Metab; 2017 May; 102(5):1702-1711. PubMed ID: 28323917 [TBL] [Abstract][Full Text] [Related]
12. Scoliosis in Prader-Willi syndrome: prevalence, effects of age, gender, body mass index, lean body mass and genotype. de Lind van Wijngaarden RF; de Klerk LW; Festen DA; Hokken-Koelega AC Arch Dis Child; 2008 Dec; 93(12):1012-6. PubMed ID: 18263693 [TBL] [Abstract][Full Text] [Related]
13. Outcomes of growth hormone treatment in children with Prader-Willi syndrome over a 30-year period: a single tertiary center experience. Gamage DS; Ambler G; Chan A; Srinivasan S; Maguire AM; Cho YH J Pediatr Endocrinol Metab; 2024 Aug; 37(8):680-685. PubMed ID: 39089289 [TBL] [Abstract][Full Text] [Related]
14. Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial. Bakker NE; Siemensma EP; Koopman C; Hokken-Koelega AC Horm Res Paediatr; 2015; 83(5):321-31. PubMed ID: 25764996 [TBL] [Abstract][Full Text] [Related]
15. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects. Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Schroor EJ; Van Alfen AA; Van Leeuwen M; Van Pinxteren-Nagler E; Van Wieringen H; Vreuls RC; Zwaveling-Soonawala N; de Ridder MA; Hokken-Koelega AC J Clin Endocrinol Metab; 2013 Oct; 98(10):4013-22. PubMed ID: 24001750 [TBL] [Abstract][Full Text] [Related]
16. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database). Craig ME; Cowell CT; Larsson P; Zipf WB; Reiter EO; Albertsson Wikland K; Ranke MB; Price DA; Clin Endocrinol (Oxf); 2006 Aug; 65(2):178-85. PubMed ID: 16886957 [TBL] [Abstract][Full Text] [Related]
17. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study. Whitman BY; Myers S; Carrel A; Allen D Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245 [TBL] [Abstract][Full Text] [Related]
18. Sleep-related breathing disorders in prepubertal children with Prader-Willi syndrome and effects of growth hormone treatment. Festen DA; de Weerd AW; van den Bossche RA; Joosten K; Hoeve H; Hokken-Koelega AC J Clin Endocrinol Metab; 2006 Dec; 91(12):4911-5. PubMed ID: 17003096 [TBL] [Abstract][Full Text] [Related]
19. Circulating insulin-like growth factor 1 levels are reduced in very young children with Prader-Willi syndrome independent of anthropometric parameters and nutritional status. Koizumi M; Konishi A; Etani Y; Ida S; Kawai M Clin Endocrinol (Oxf); 2022 Mar; 96(3):346-352. PubMed ID: 34750859 [TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study. Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Troeman ZC; van Alfen-van der Velden AA; Otten BJ; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Oostdijk W; Bocca G; Mieke Houdijk EC; van Trotsenburg AS; Hoorweg-Nijman JJ; van Wieringen H; Vreuls RC; Jira PE; Schroor EJ; van Pinxteren-Nagler E; Willem Pilon J; Lunshof LB; Hokken-Koelega AC J Clin Endocrinol Metab; 2012 Jul; 97(7):2307-14. PubMed ID: 22508707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]